- Dafna Groeneveld, Michigan State University – USA
Novel hemostatic supplementation to prevent post-operative liver failure after partial hepatectomy
- Pieter Sloos, Amsterdam University Medical Centers – The Netherlands
The role of ADAMTS13 in trauma-induced hyperfibrinolysis
- Steven Grover, University of North Carolina – USA
Evaluating the anticoagulant activity of C1 esterase inhibitor (C1INH) in venous thrombosis
- Daniëlle Meijer, Radboud University Medical Center – The Netherlands
Phenotypical differences between carriers of von Willebrand disease type 3 and von Willebrand disease type 1 patients
- Iris van Moort, Erasmus University Medical Center – The Netherlands
Orchestrating all hemostatic components in an in-vitro bleeding model to unravel the inter-individual treatment responses of patients with von Willebrand’s disease
Professor Heimburger Award
Professor Dr. Norbert Heimburger, a CSL Behring employee for over three decades, was a pioneer of modern coagulation therapy. Among his many achievements, Prof. Dr. Heimburger developed virus-safe plasma products based on pasteurization, including launching the first effectively virus-inactivated FVIII concentrate in 1981.
In his honor, CSL Behring created the Heimburger Award to recognize the clinical and/or preclinical research of emerging coagulation specialists who are driven to improve the care of patients with bleeding disorders. Read our newsletter.
Global Research Grant
CSL Behring is committed to supporting progress in the area of coagulation in the long run. Based on recent publications and feedback from the medical community, allowing the next generation of coagulation specialists to medically and scientifically establish themselves, it is important to ensure continued progress in this therapeutic area.
Grant Details and Eligibility
CSL Behring will set five global start-up grants of €25,000 each.
The grants are reserved for researchers who hold a medical degree or a PhD. Applicants with less than five years of faculty experience in hemostasis will be preferred.
No matching funding is a prerequisite for this grant. The grants will be available for clinical and/or preclinical research in the area of coagulation.
Application and Procedure
Applications for the 2023 cycle will open from August 1, 2022; applications consisting of an application form, a short CV and a one-page research proposal must be received by November 7, 2022 in order to be considered. Applications should be submitted in English.
For inquiries regarding application, policy and procedures information, please contact the Heimburger Award Facilitator at email@example.com